Direct costs of epidermolysis bullosa by disease severity by Flannery, Darragh et al.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
SHORT COMMUNICATION
1/2
Acta Derm Venereol 2020; 100: adv00116
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta
Journal Compilation © 2020 Acta Dermato-Venereologica.
doi: 10.2340/00015555-3456
The condition epidermolysis bullosa (EB) is a genetic, 
rare skin condition, where the skin of a patient is abnor-
mally fragile. Due to a genetic abnormality, the layers 
of the skin do not adhere to each other adequately and 
thus even minimal physical contact can cause bliste-
ring, sores and severe pain. EB prevalence is estimated 
at 1/18,000 live births (1, 2) EB has been separated 
into different subtypes, based on the ultrastructural 
level within which blisters develop in affected tissues 
(3). The 3 most prevalent sub-types are: EB simplex 
(EBS), junctional EB (JEB) and dystrophic EB (DEB). 
EB simplex is the most common and usually the least 
severe form; blistering is often localised and lesions 
heal without scarring. Junctional EB, recessive dys-
trophic EB and EB simplex generalised severe, on the 
other hand, tend to be less common and are often more 
severe for the patient. 
There are currently no effective treatments or cures 
for EB and management focuses on amelioration of the 
symptoms. Treatments are, however, in development 
and are likely to be expensive because the condition is 
rare. It will be necessary to compare the cost of new 
treatments with the cost of not treating, in order to make 
informed budget decisions. However, given the rarity of 
EB, there has been minimal research conducted from a 
cost viewpoint. Indeed, Angelis et al. (1) highlight the 
lack of research in this area. Tabolli et al. (4) provide 
survey evidence of high family burdens related to EB 
from a psychological distress viewpoint. Brun et al. (5) 
also use patient survey data and show that those with 
EB to have frequent and severe pain with neuropathic 
characteristics, with this pain negatively affecting 
quality of life. The only study identified to date that 
considers cost issues related to EB is that of Angelis 
et al. (1). This study utilised a bottom up patient sur-
vey and showed mean costs ranging from €46,000 per 
annum in Germany to €9,500 in Sweden. It was also 
notable that informal care costs formed a large propor-
tion of the overall total for each country and that costs 
for paediatric patients were considerably higher than 
for adults. We conducted a similar study for the case 
of Ireland using a sample of paediatric patients. We 
differentiate our study from that of Angelis et al. (1) 
by providing more in depth analysis specific to wound 
care costs and costs across a subjective measure of the 
severity of the condition.  
MATERIALS AND METHODS
Similar to Angelis et al. (1), we used a prevalence based approach 
using a sample of households with someone with a child < 18 
diagnosed with EB who received outpatient care to estimate the 
resources used and thus the social costs of the disease. The study 
protocol was submitted to the Kemmy Business School, Univer-
sity of Limerick (UL) Research Ethics Committee and received 
an exemption (respondents were recruited with the assistance 
of DEBRA Ireland). All patients and caregivers were informed 
about the study objective, data confidentiality and were asked to 
indicate their consent to participate. As the information related to 
those under 18, the main care provider of the patient completed 
the survey in either a face to face manner or by post. 
Information on drug, wound care and various medical service 
utilisation as well as basic socioeconomic information was col-
lected on a total of 6 patients with respect to the previous month; 
5 children aged between 2 and 18 and one infant aged 9 months. 
Cost information for the hospital stays (€813 per night based on 
semi private room) and day hospital clinic visits (€407) were 
taken from the Irish Health Service Executive’s (HSE) guide on 
service prices (available at https://www.hse.ie/eng/about/who/
acute-hospitals-division/patient-care/hospital-charges/). Primary 
care usage stemmed mainly from visit to general practitioners 
but also included physiotherapy, occupational therapy and public 
health nurse visits. To obtain separate cost information for each of 
these separately proved extremely difficult, therefore the mean GP 
visit charge in Ireland of €52.50 (6) for each primary care event 
was used as a proxy. The HSE’s Primary Care Reimbursement 
Service list of reimbursable items (available at https://www.ssp-
crs.ie/druglist/pub) provided the unit cost information for wound 
and drug utilised (e.g. the unit price of a common dressage used 
by our sample, Mepilex Transfer 20x50cm was €37.20 as per the 
HSE guidelines).
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Table I. Summary of mean costs across 12 month period for those aged 2–18 years by severity
Age, years 2.5 7 10 8 9
EB type RDEB RDEB RDEB EB simplex RDEB
Severity Very severe Very severe Very severe Mild Moderate
Wound and drugs cost (€) 27,252 89,780 62,699 17,732 5,986
Overnight hospital costs (€) 39,837 56,910 28,455 0 0
Day clinic costs (€) 2,442 1,628 20,350 2,442 814
Other primary care costs (€) 1,890 1,102 5,145 105 577
Total medical costs per annum (€) 71,421 149,421 116,649 20,279 7,377
EB: epidermolysis bullosa; RDEB: recessive dystrophic EB
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RESULTS
The sample is presented on a per patient basis with an 
infant as a stand-alone study and the older children 
summarised separately. Table I focuses on the latter and 
presents the costs across a 12-month period for those 
aged 2.5–10 by severity of illness and EB type. The di-
rect costs estimated for our sample range from €149,421 
to €7,377, the former representative of a patient with a 
very severe condition with the latter reflecting a patient 
with a milder form. The 3 other very severe patients also 
exhibit high costs at €71,421 and €116,649, respectively. 
It is notable that wound and drug costs are considerably 
higher for those with more severe conditions with the 
high utilisation of wound dressings such as Mepilex 
Transfer and Urgotul a significant driver of these high 
costs. Table II presents a summary of the mean costs for 
the first 12 months of life based upon our case study of 
one infant with severe EB. This highlights the significant 
contribution that hospital admittance has in costs at the 
early stage of life for those with severe EB rather than 
wound care costs, contributing around 90% of the overall 
cost of €118,665.
DISCUSSION
This short report contributes to the relatively sparse lite-
rature on the economic cost of the rare skin disease EB 
and suggest significant variation in these costs for young 
people dependent on severity. It also highlights the po-
tential high hospital costs involved in the first year of life 
associated with the disease. This study has the obvious 
limitation of a small sample size, however, the estimates 
helps to demonstrate the high degree of heterogeneity in 
social costs from EB depending on the severity of the 
disease and thus contribute to knowledge in the area. The 
cost estimates for the mild-moderate sample are very 
comparable to those estimated in Angelis et al. (1) while 
the costs for the more severe cases in our sample are 
considerable higher. However, the Barthel index scores 
(mean of 85.2) from the Angelis paper indicate that their 
sample was mainly drawn from more mild to moderate 
cases and thus help explain the differences seen here. 
Future research in the area may focus upon more severe 
cases of EB, particularly the informal hours dedicated. 
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Table II. Summary of mean costs for first 12 months of life
Severe EB Euro
Wound and drugs cost     8,303
Overnight Hospital costs 104,560
Day Clinic costs     2,442
Other Primary care costs     3,360
Total Medical costs per Annum 118,665
